Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting
Blanco-Grau, Albert (Vall d'Hebron Institut de Recerca (VHIR))
Gabriel-Medina, Pablo (Vall d'Hebron Institut de Recerca (VHIR))
Rodriguez-Algarra, Francisco (Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK)
Villena-Ortiz, Yolanda (Vall d'Hebron Institut de Recerca (VHIR))
Lopez-Martínez, Rosa (Hospital Universitari Vall d'Hebron)
Augustin Recio, Salvador (Hospital Universitari Vall d'Hebron)
Pons Delgado, Mònica (Hospital Universitari Vall d'Hebron)
Cruz Carlos, Luz Maria (Hospital Universitari Vall d'Hebron)
Rando-Segura, Ariadna (Hospital Universitari Vall d'Hebron)
Enfedaque Montes, Belen (Institut Català de la Salut)
Riveiro Barciela, Mar (Universitat Autònoma de Barcelona. Departament de Medicina)
Casis-Saez, Ernesto (Hospital Universitari Vall d'Hebron)
Ferrer Costa, Roser (Hospital Universitari Vall d'Hebron)
Buti, Maria (Universitat Autònoma de Barcelona. Departament de Medicina)
Rodríguez Frías, Francisco (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)

Data:	2021
Resum:	Liver disease is frequently asymptomatic, challenging early identification in the primary care setting. The fibrosis 4 (FIB4) index is a liver fibrosis biomarker that is a potential alternative to liver biopsy for diagnosing and managing liver disease. This study aimed to calculate the FIB4 index for screening individuals at high risk of liver disease at the community level. This was a retrospective real-world study analyzing blood and serum test results from a central laboratory. The primary outcome was the number of individuals within each risk category for hepatic fibrosis: high risk (FIB4 ≥ 3. 25) and low risk (FIB4 < 1. 3). The analysis included samples from 31,753 patients, of which 18,102 were aged 40 to 75 years. In these patients, the FIB4 index had been explicitly requested in 1852 (10. 2%) cases and estimated ad hoc in the rest. Of the 263 (1. 5%) cases with FIB4 ≥ 3. 25, the FIB4 index was requested in 46 (17. 5%), and 52 (19. 8%) showed evidence of liver fibrosis in their medical records, while the rest did not report any data regarding liver fibrosis. FIB4 is a simple score that can play a role as a "red flag" for early identification of patients at high risk of advanced liver fibrosis and their referral to specialized care.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Chronic liver disease ; Liver fibrosis ; Metabolic associated fatty liver disease (MAFLD) ; Screening ; Fibrosis 4 score
Publicat a:	Diagnostics, Vol. 11, Num. 12 (november 2021) , ISSN 2075-4418

DOI: 10.3390/diagnostics11122236
PMID: 34943471

10 p, 284.8 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats